Genome Research

Mount Sinai Researchers Find More Than 4,700 Gene Clusters Crucial for Prognosis in 32 Cancer Types

Retrieved on: 
Monday, November 13, 2023
Doctor of Philosophy, Research, Cancer, Genome Research, TCGA, Human Genome Sciences, The Cancer Genome Atlas, Vaccine, Genetics

NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.
  • Previous research often focused on isolated gene functions in specific cancer types.
  • We have identified 4,749 distinct co-regulated gene modules that play a pivotal role in cancer progression," explained Dr. Zhang.
  • "Our findings offer fertile ground for the next wave of cancer research and treatment strategies," said Dr. Zhang.

Dr. Steven Barnard Appointed Chief Technology Officer

Retrieved on: 
Wednesday, August 9, 2023
Tufts University, Connecticut College, DNA, Interim, Analytical chemistry, Partnership, Doctor of Philosophy, Rady Children's Hospital, Research, Chemistry, SAN, Genome Research, Protein engineering, Hospital, Health, Genome, Illumina, Inc., Management, Science, Nature, Illumina

SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina's Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately.

Key Points: 
  • SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina's Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately.
  • Dr. Barnard joined Illumina in 1998 as the company's first scientist and fourth employee, holding a variety of leadership positions within Illumina's R&D organization throughout his distinguished 25-year tenure.
  • Through critical roles in research and technology development, Barnard contributed significantly to maturing Illumina's foundational science technologies including synthetic chemistry, protein engineering, surface science, assay research and nanofabrication.
  • He brings expansive institutional knowledge of our entire technology portfolio and will help Illumina continue to deliver on its important mission," said Charles Dadswell, Interim Chief Executive Officer at Illumina.

Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives

Retrieved on: 
Thursday, July 20, 2023
Amgen, Stanford University, MBA, Employment, Acquisition, Patient, Diversity, Inclusion, Principal, Compensated emancipation, Corporate development, Boston Consulting Group, Orexigen Therapeutics, Business development, University, Therapy, Arena Pharmaceuticals, American InterContinental University, Lonza, Organization development, Research, Strategic planning, Gilead, Coulter, Corporation, Knowledge, Growth, Amylin Pharmaceuticals, III, Genome, Business, Whitehead, University of Miami, Reflexive relation, Genome Research, Human, Economics, BA, Human resources, Federal Reserve Board of Governors, TAC, Pharmaceutical industry, Management, Biochemistry, Pomona College, Cain (Italian band)

Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.

Key Points: 
  • Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.
  • Mr. Williamson has successfully led multiple companies through significant growth, partnerships, financing rounds, IPOs, and successful acquisitions.
  • Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations.
  • Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute).

Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors

Retrieved on: 
Monday, July 10, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, IPO, Broad Institute, Central nervous system, University, Midas List, General partnership, Iron monosilicide, RNA, Conditional, Patient, Genome Research, Novo Nordisk, RNA interference, Therapy, Broad, Disease, Pharmaceutical industry, Vaccine

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
  • With an incredible track record of building successful RNA companies, Doug will bring strategic perspective as we advance CASi and continue to build our pipeline,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “I am honored to join the Switch Therapeutics Board of Directors and believe deeply in the promise of gene knockdown to address an array of unmet needs,” said Dr. Fambrough.
  • I look forward to partnering with the Switch team to advance the company’s pipeline and, ultimately, deliver important new medicines that dramatically improve patients’ lives.”

New Study Shows Improved Genotyping by Sequencing with in vitro Repeat Depletion

Retrieved on: 
Tuesday, June 20, 2023
University, Noise, Genomics, SAN, Genome Research, Biology, University of Verona, Polytechnic, Agriculture

SAN DIEGO, June 20, 2023 /PRNewswire/ -- Jumpcode Genomics , a genome technology platform company focused on improving the understanding of human biology, today announced the results of a study demonstrating the ability to improve genotyping through CRISPR-Cas9-based in vitro repeat depletion, a new method for high-throughput genotyping where repetitive fragments are removed prior to genotyping with low-pass sequencing.

Key Points: 
  • SAN DIEGO, June 20, 2023 /PRNewswire/ -- Jumpcode Genomics , a genome technology platform company focused on improving the understanding of human biology, today announced the results of a study demonstrating the ability to improve genotyping through CRISPR-Cas9-based in vitro repeat depletion, a new method for high-throughput genotyping where repetitive fragments are removed prior to genotyping with low-pass sequencing.
  • The study, published in the journal Genome Research , shows how Jumpcode Genomics' depletion technology can be used to remove repetitive elements from genome sequencing libraries, allowing for more accurate genotyping of coding and regulatory regions.
  • The researchers also observed an increased genotyping accuracy by rescuing thousands of heterozygous variants that otherwise would be missed due to low coverage.
  • We are excited to see our depletion technology have another meaningful impact in genomics," said Yaron Hakak, CEO of Jumpcode.

Saving declining amphibians through genetics - newly funded Morris Animal Foundation and Revive & Restore projects lay the foundation for genomic approaches to amphibian conservation

Retrieved on: 
Tuesday, April 11, 2023
Tao, Sequence, CRISPR, IUCN, University, Agriculture, Batrachochytrium dendrobatidis, Hope, University of California, Medicine, Genomics, Telmatobufo venustus, Tylototriton vietnamensis, Amphibian, Revive, International Union for Conservation of Nature, Genome Research, Morris Animal Foundation, Revive & Restore, Conservation, Telmatobufo, Atelopus, Habitat, Genome, Hunting, Research

DENVER, April 11, 2023 /PRNewswire/ -- Morris Animal Foundation and Revive & Restore recently announced the funding of five new projects building genomic tools for amphibian conservation.

Key Points: 
  • DENVER, April 11, 2023 /PRNewswire/ -- Morris Animal Foundation and Revive & Restore recently announced the funding of five new projects building genomic tools for amphibian conservation.
  • "Amphibian populations are declining at an alarming rate around the world," said Dr. Kathy Tietje, Chief Program Officer at Morris Animal Foundation.
  • "These newly funded projects will leverage advanced genomic approaches to create new conservation strategies."
  • "The selected projects have important conservation applications today, and lay the foundation for future genomic technologies that can help rescue amphibian populations."

Swedish Olink technology enables further development of South African research and innovation

Retrieved on: 
Wednesday, March 29, 2023
IDM, COVID-19, Infection, Hope, DSI, Research, Proteomics, Flex, Molecular medicine, Patient, Tuberculosis, Metabolomics, Genome Research, Knowledge, Vaccine, Pharmaceutical industry

D-CYPHR enables access to proteomics and metabolomics platforms and knowledge, supporting complex clinical and biological research not possible elsewhere in this region.

Key Points: 
  • D-CYPHR enables access to proteomics and metabolomics platforms and knowledge, supporting complex clinical and biological research not possible elsewhere in this region.
  • Among the first projects to benefit from Olink technology will be those directed toward COVID-19 and tuberculosis research.
  • “Olink is immensely proud to see our technology contributing to the outstanding research efforts in South Africa.
  • We know that our technology will further stimulate the development of groundbreaking science, enhancing the well-being of people around the world,” said Jon Heimer, CEO of Olink.

Insights on the Ultra-low Temperature Freezers Global Market to 2027 - Rise In R&D Activities To Introduce New Drug Compounds Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Other Manufacturing, Manufacturing, Observation, Global, Porter's five forces analysis, Biotechnology, COVID-19, Competitive analysis, Risk, Hospital, Academy, Geography, Growth, Forensic science, Ansoff Matrix, Industry, Market development, Bad Blood (Blood on the Dance Floor album), USD, Emotion, Investment, Others, ULT freezer, Genome Research, SWOT, Research institute, CAGR, Marketing, Retail, Risk management, Pharmaceutical industry, Automation, Application, Automatic, Technology

The report presents a detailed Ansoff matrix analysis for the Global Ultra-low Temperature Freezers Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global Ultra-low Temperature Freezers Market.
  • The Global Ultra-low Temperature Freezers Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Ultra-low Temperature Freezers Market.
  • The Global Ultra-low Temperature Freezers Market is segmented based on Product, Cooling, Application, Technology, Defrosting Type, End-user, and Geography.

Strains--not Species--of Gut Microbes Hold Key to Health and Disease

Retrieved on: 
Thursday, December 23, 2021
DNA, Genome Research, Physics, Stanford University, Genome, Technology, Communication, Doctor of Philosophy, GT Pro Series, Disease, Data science, Autism, Memory, National Science Foundation, Time, Lyme disease, UC, University of California, San Francisco, Biohub, Gladstone Institutes, Longitudinal, Food, Diabetes, Diet, Biotechnology, Bacteria, Environment, Method, University, Database, Collection, Health, Algorithm, Asthma, Sequence alignment, Inflammatory bowel disease, Genotyping, Berkeley, Nature Biotechnology, Cancer, SAN, Media contacts database, Research, Multimedia, Ecosystem, Genetic code, Dietary supplement, Antibiotics, Vaccine, Whaling, Public relations, Pharmaceutical industry

Scientists know that this ever-shifting balance of gut microbes is linked to your health and disease, but have struggled to pin down what makes one microbial balance better than another.

Key Points: 
  • Scientists know that this ever-shifting balance of gut microbes is linked to your health and disease, but have struggled to pin down what makes one microbial balance better than another.
  • The new approach, Pollard says, will enable researchers to carry out bigger and more precise analyses of the microbiome than ever before.
  • The researchers analyzed over 100,000 publicly available and high-quality genomes from approximately 900 bacterial species commonly found in the human gut.
  • Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease.

ImmixBio Announces Dr. Galit Lahav of Harvard Medical School Joins Scientific Advisory Board

Retrieved on: 
Tuesday, August 17, 2021
Behavior, MD, Inflammatory bowel disease, Mentorship, Cancer, Genomics, Harvard Medical School, Leadership, Science, Biology, Ulcerative colitis, Harvard University, Genome Research, Weizmann Institute of Science, Disease, Doctor of Philosophy, Health, Inflammation, TME, Biotechnology, Clinical trial, United States Air Force Scientific Advisory Board, Crohn's disease, Lahav, CEO, Faculty, Novartis, Systems biology, Woman, Department, Pharmaceutical industry

LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx) for oncology and inflammation, today announced that Galit Lahav, PhD, Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School has joined its Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx) for oncology and inflammation, today announced that Galit Lahav, PhD, Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School has joined its Scientific Advisory Board.
  • "I am delighted to welcome Dr. Galit Lahav to our Scientific Advisory Board.
  • Dr. Lahav is the Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School.
  • She then spent a year at Harvard's Bauer Center for Genomics Research, and in 2004 joined the Department of Systems Biology at Harvard Medical School.